The RENAL1 and ATN2 studies represent a substantial improvement in patient outcomes compared to previous studies over the last 10 years involving patients with similar illness severity.
The BEST kidney study3 and the SWING study4 were observational analyses comparing the choice of CRRT to IHD for initial treatment of AKI patients.
The BEST kidney study shows:
An 85% renal recovery rate* for patients treated initially with CRRT vs. 66.1% for patients treated at the outset with IRRT. (P<0.0001)
The SWING study indicates:
Cumulative incidence of permanent renal failure was 8.3% in CRRT group vs. 16.5% in the IHD group.**
In addition, CRRT facilitates fluid overload management, which has been associated with increased mortality in AKI patients. CRRT may also maintain hemodynamic stability in critically ill AKI patients when compared to IRRT.
Now is the right time to consider the expanding body of clinical data that details the benefits of CRRT in treating critically ill AKI patients.
*Results measured in surviving patients at hospital discharge.
**Results measured in surviving patients at 90 days.